Screener
Corcept Therapeutics CORT Accrued research and development expenses
Accrued research and development expenses at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept cort:AccruedResearchAndDevelopmentExpensesCurrent.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $14,910 | $40,444 |
| Accrued research and development expenses | 21,628 | 33,954 |
| Accrued and other liabilities | 115,347 | 90,603 |
| Short-term operating lease liability | 1,917 | 1,084 |
| Total current liabilities | 153,802 | 166,085 |
| Long-term operating lease liability | 7,504 | 5,023 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's accrued research and development expenses?
- Corcept Therapeutics (CORT) reported accrued research and development expenses of $21.63M in Q2 2026.
- How has Corcept Therapeutics's accrued research and development expenses changed year-over-year?
- Corcept Therapeutics's accrued research and development expenses decreased by 25.5% year-over-year, from $29.05M to $21.63M.
- What is the long-term trend for Corcept Therapeutics's accrued research and development expenses?
- Over 4 years (2021 to 2025), Corcept Therapeutics's accrued research and development expenses has grown at a 28.5% compound annual growth rate (CAGR), from $12.44M to $33.95M.
- What does accrued research and development expenses mean?
- This reflects the estimated costs incurred for research and development activities that have not yet been invoiced or paid by the reporting date. For pharmaceutical companies, this is a critical measure of ongoing clinical trial and drug development activity.
Ask your AI about Corcept Therapeutics's accrued research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude